Article

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort Study

2022-05-23

Abstract excerpt

<h4>Background</h4> The safety of SARS-CoV-2 vaccines is unknown in children aged <5 years. Here, we retrospectively evaluated the safety of BNT162b2 vaccine used off-label in children of this age group in Germany. <h4>Methods</h4> An investigator-initiated retrospective cohort study (CoVacU5) included parents or caregivers having children aged <5 years registered for SARS-CoV-2 vaccination in outpatient care faci...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e7d59849-2c15-57cb-aa20-a9428b23c088
DOI: 10.1101/2022.05.17.22275005

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudyDOI 10.1101/2022.05.17.22275005Read

Sex differences in symptoms following the administration of BNT162b2 mRNA Covid-19 Vaccine in Children below 5 Years of age in Germany (CoVacU5): a retrospective cohort studySemantic proximity Read

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United StatesSemantic proximity Read

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsSemantic proximity Read

Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescentsSemantic proximity Read

Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity Read

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity Read

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialSemantic proximity Read

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 YearsSemantic proximity Read

Vaccination against SARS-CoV-2 in UK school-aged children and young people decreases infection rates and reduces COVID-19 symptomsSemantic proximity Read

Comprehensive antibody profiling of mRNA vaccination in childrenSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read